RECENT PUBLICATIONS

1. Seibold JR, Benza R, Davie N, Frost A, Gaine S, Hill NS, Highland K, Langleben D, Naeije R: One-year open label comparison of sitaxentan to bosentan in treatment of pulmonary arterial hypertension related to systemic sclerosis.  Ann Rheum Dis (in press).
   
   
2. Seibold JR, Benza R, Davie N, Frost A, Gaine S, Hill NS, Highland K, Langleben D, Naeije R: Long term results of sitaxentan therapy in pulmonary arterial hypertension associated with connective tissue disease.  Ann Rheum Dis (in press).
   
   
3. Phillips K, Byrne-Dugan C, Batterson E, Seibold JR: Rapidly progressive fatal interstitial lung disease in a patient with systemic sclerosis. Nature Reviews Rheumatology 5:225-228, 2009
   
   
4. Hsu VM, Shinnar M, Moreyra AE, Wilson AC, Shinnar M, Shindler DM, Wilson JE, Desai A, Seibold JR.  Assessment of pulmonary arterial hypertension in patients with systemic sclerosis:  A comparison of Doppler echocardiography, cardiac MRI, and pulmonary function test to right heart catheterization. J Rheumatol 35:458-465, 2008.
   
   
5. Merkel PA, Silliman NP, Denton CP, Furst DE, Khanna D, Emery P, Hsu VM, Streisand JB, Polisson RP, Akesson A, Coppock J, van den Hoogen F, Herrick A, Mayes MD, Veale D, Seibold JR, Black CM and Korn JH for the CAT-192 Research Group and the Scleroderma Clinical Trials Consortium.  Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial.  Arthritis Care Res 59:699-705, 2008.
   
   
6. Strange C, Seibold JR.  Scleroderma lung disease:  If you don’t know where you are going, any road will take you there.  Am J Respir Crit Care Med 177:1178-79, 2008.
   
   
7. Distler O, Behrens F, Pittrow D, Huscher D, Denton CP, Foeldvari I, Humbert, Matucci-Cerinic M, Nash P, Opitz C, Rubin L, Seibold JR and Furst DE.  Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis:  Delphi consensus study with cluster analysis.  Arthritis Rheum 59(6):867-875, 2008.
   
   
8. Impens AJ, Wangkaew S, Seibold JR: The six-minute walk test in scleroderma – how measuring everything measures nothing. Rheumatology 47: v68-v69, 2008.
   
   
9. Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver R, Goldin J, Arriola E, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel D, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M.  Effects of a one-year treatment with cyclophosphamide on outcomes at two years in scleroderma lung disease.  Am J Resp Crit Care Med 176:1026-1034, 2007.
   
   
10. Nash RA, McSweeney PA, Crofford LJ, Abidi M, Chen CS, Godwin D, Gooley TA, Holmberg L, Henstorf G, LeMaistre CF, Mayes M, McDonagh KT, McLaughlin B, Molitor J, Nelson JL, Shulman H, Storb R, Viganego F, Wener M, Seibold JR, Sullivan KM, Furst DE.  High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis:  U.S. multicenter pilot study.  Blood 110(4):1388-96, 2007.
    
    
11. Buch MH, Denton CP, Furst DE, Guillevin L, Rubin LJ, Wells AU, Matucci-Cerinic M, Riemkasten G, Emery P, Chada-Boreham H, Charef P, Roux S, Black CM, Seibold JR.  Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the six minute walk test. Ann Rheum Dis 66:169-173, 2007.
    
    
12. Denton CP, Merkel PA, Furst DE, Khanna D, Emery P, Hsu VM, Silliman N, Streisand J, Powell J, Akesson A, Coppock J, van den Hoogen F, Herrick A, Mayes MD, Veale D, Ledbetter S, Korn JH, Black CM, Seibold, JR: Recombinant human anti-TGFβ1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo-controlled Phase I/II Trial of CAT-192. Arthritis Rheum 56(1):323-333, 2007.
    
    
13. Khanna D, Yan X, Tashkin DP, Furst DE, Elashoff R, Roth MD, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel D, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M, Clements PJ.  Impact of oral cyclophosphamide on health-related quality of life in patients with scleroderma lung disease with active alveolities – results from the scleroderma lung study. Arthritis Rheum 56(5):1676-1684, 2007.
    
    
14. Seibold JR.  Endothelin receptor antagonism is the treatment of choice in scleroderma pulmonary hypertension.  Nature Clin Pract Rheum.  3(4):204-5, 2007.
    
    
15. Girgis RE, Frost AE, Hill NS, Horn EM, Langleben D, McLaughlin VV, Oudiz RJ, Robbins IM, Seiboid JR, Shapiro S, Tapson VF, Barst RJ.  Selective endothelinA antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease.  Ann Rheum Dis doi:10.1136/ard 2007, 069609 and 2007; 66:1467-1472.
    
    
16. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel D, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M: Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354:2655-66, 2006.
    
    

Back to About Us - Top of Page